NO20054789L - Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon - Google Patents

Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon

Info

Publication number: NO20054789L
Authority: NO; Norway
Prior art keywords: tazobactam; useful; piperaciliin; injection; compositions containing
Prior art date: 2003-04-14

Application number

NO20054789A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054789D0 (no

Inventor

Syed Muzafar Shah

Jonathan Marc Cohen

Christian Luther Ofslager

Mahdi Bakir Fawski

Original Assignee

Wyeth Holdings Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-14

Filing date

2005-10-18

Publication date

2005-12-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054789(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-18 Application filed by Wyeth Holdings Co filed Critical Wyeth Holdings Co

2005-10-18 Publication of NO20054789D0 publication Critical patent/NO20054789D0/no

2005-12-13 Publication of NO20054789L publication Critical patent/NO20054789L/no

Links

239000000203 mixture Substances 0.000 title abstract 3
238000002347 injection Methods 0.000 title 1
239000007924 injection Substances 0.000 title 1
LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 title 1
229960003865 tazobactam Drugs 0.000 title 1
LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 abstract 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
229940126575 aminoglycoside Drugs 0.000 abstract 1
239000008365 aqueous carrier Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000002738 chelating agent Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
229940104641 piperacillin / tazobactam Drugs 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20054789A 2003-04-14 2005-10-18 Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon NO20054789L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46280803P	2003-04-14	2003-04-14
PCT/US2004/010698 WO2004091666A1 (fr)	2003-04-14	2004-04-07	Compositions contenant de la piperacilline et du tazobactam pour injection

Publications (2)

Publication Number	Publication Date
NO20054789D0 NO20054789D0 (no)	2005-10-18
NO20054789L true NO20054789L (no)	2005-12-13

Family

ID=32326726

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054789A NO20054789L (no)	2003-04-14	2005-10-18	Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon

Country Status (34)

Country	Link
US (3)	US7498312B2 (fr)
EP (1)	EP1468697B1 (fr)
JP (1)	JP4644659B2 (fr)
KR (1)	KR100824554B1 (fr)
CN (1)	CN1802179B (fr)
AR (1)	AR043863A1 (fr)
AT (1)	ATE381947T1 (fr)
AU (1)	AU2004229407B2 (fr)
BR (1)	BRPI0409450B8 (fr)
CA (1)	CA2464258C (fr)
CH (1)	CH695185A9 (fr)
CL (1)	CL2004000782A1 (fr)
CO (1)	CO5700796A2 (fr)
CR (2)	CR8035A (fr)
CY (1)	CY1108064T1 (fr)
DE (1)	DE602004010862T2 (fr)
DK (1)	DK1468697T3 (fr)
EC (1)	ECSP056100A (fr)
ES (1)	ES2298672T3 (fr)
FR (1)	FR2853547B1 (fr)
GB (1)	GB2400557B (fr)
IL (1)	IL171337A (fr)
MX (1)	MXPA05010996A (fr)
MY (1)	MY139099A (fr)
NO (1)	NO20054789L (fr)
NZ (1)	NZ543005A (fr)
PL (1)	PL1468697T3 (fr)
PT (1)	PT1468697E (fr)
RU (2)	RU2322980C2 (fr)
SA (1)	SA04250119B1 (fr)
SI (1)	SI1468697T1 (fr)
TW (1)	TWI308069B (fr)
WO (1)	WO2004091666A1 (fr)
ZA (1)	ZA200508315B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004057959A2 (fr) *	2002-12-20	2004-07-15	Generipharm, Inc.	Injection intracutanee
ES2298672T3 (es) *	2003-04-14	2008-05-16	Wyeth Holdings Corporation	Composiciones que contienen piperacilina y tazobactam utiles para inyeccion.
RU2007111484A (ru) *	2004-10-14	2008-11-20	Вайет (Us)	Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия
UA91204C2 (ru) *	2004-12-02	2010-07-12	Ману Чаудхарі	Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции
ES2284318B1 (es) *	2005-04-13	2008-11-01	Labiana Development, S.L.	Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it)	2005-09-02	2007-03-03	Acs Dobfar Spa	Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN101129383B (zh) *	2006-08-25	2014-04-02	天津和美生物技术有限公司	含氨基糖苷类抗生素的抗生素复方
CN102441169A (zh) *	2006-08-25	2012-05-09	天津和美生物技术有限公司	含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh)	2006-08-25	2013-12-25	天津和美生物技术有限公司	含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) *	2006-08-25	2012-02-01	天津和美生物技术有限公司	含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN1927201B (zh) *	2006-08-25	2011-06-01	天津和美生物技术有限公司	含哌拉西林的抗生素复方
CN102210679B (zh) *	2006-08-25	2013-03-13	天津和美生物技术有限公司	含哌拉西林的抗生素复方
CN101265263B (zh) *	2008-05-12	2010-06-02	海南百那医药发展有限公司	哌拉西林钠他唑巴坦钠复方注射剂的生产方法
WO2010013640A1 (fr) *	2008-07-28	2010-02-04	Yamaguchi Keizo	Potentialisateur d'efficacité thérapeutique sur une maladie infectieuse
JP5852316B2 (ja) *	2010-03-30	2016-02-03	富山化学工業株式会社	ピペラシリン含有懸濁液の製造法
US20120046225A1 (en)	2010-07-19	2012-02-23	The Regents Of The University Of Colorado, A Body Corporate	Stable glucagon formulations for the treatment of hypoglycemia
ES2859639T3 (es)	2010-11-25	2021-10-04	Allecra Therapeutics Gmbh	Compuestos y su uso
CN105853348B (zh)	2011-03-10	2019-08-30	Xeris药物公司	肠胃外注射用稳定溶液
ES2574761T3 (es)	2011-10-31	2016-06-21	Xeris Pharmaceuticals, Inc.	Formulaciones para el tratamiento de la diabetes
SG10201607872PA (en)	2012-03-26	2016-11-29	Santen Pharmaceutical Co Ltd	Ophthalmic solution comprising diquafosol
US9125805B2 (en)	2012-06-27	2015-09-08	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) *	2012-09-27	2013-07-02	Cubist Pharmaceuticals, Inc.	Tazobactam arginine compositions
KR101816798B1 (ko) *	2012-10-19	2018-01-10	주식회사유한양행	피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en)	2013-02-06	2015-04-28	Xeris Pharmaceuticals, Inc.	Methods for rapidly treating severe hypoglycemia
US9320740B2 (en)	2013-03-15	2016-04-26	Merck Sharp & Dohme Corp.	Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en)	2013-03-15	2018-01-23	Merck Sharp & Dohme Corp.	Ceftolozane antibiotic compositions
EP2893929B1 (fr)	2013-03-15	2025-04-16	Merck Sharp & Dohme LLC	Compositions antibiotiques à base de ceftolozane
US10376496B2 (en)	2013-09-09	2019-08-13	Merck, Sharp & Dohme Corp.	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en)	2013-09-27	2014-12-09	Calixa Therapeutics, Inc.	Solid forms of ceftolozane
JP6382997B2 (ja)	2014-02-07	2018-08-29	エクセセーラファーマシューティカルズインコーポレイテッド	治療用化合物および組成物
AU2015300944B2 (en)	2014-08-06	2019-07-11	Xeris Pharmaceuticals, Inc.	Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
KR20170067709A (ko) *	2014-10-08	2017-06-16	사와이세이야쿠 가부시키가이샤	동결 건조 제제의 제조 방법
US9649364B2 (en)	2015-09-25	2017-05-16	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en)	2015-09-25	2023-02-28	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US20180064691A1 (en) *	2016-03-31	2018-03-08	Wockhardt Limited	Antibacterial compositions
WO2018025248A1 (fr) *	2016-08-05	2018-02-08	Jodas Expoim Private Limited	Injection d'edta et son procédé de fabrication.
WO2018222922A1 (fr)	2017-06-02	2018-12-06	Xeris Pharmaceuticals, Inc.	Formulations de médicaments à petite molécule résistantes à la précipitation
US11110054B2 (en)	2018-05-09	2021-09-07	Slayback Pharma Llc	Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) *	2020-12-24	2023-07-18	浙江昂利康制药股份有限公司	一种注射用混悬油剂及其制备方法
CN113209030B (zh) *	2021-04-27	2023-04-25	海南通用康力制药有限公司	哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法
CN119367287B (zh) *	2024-12-27	2025-03-28	成都硕德药业有限公司	一种重酒石酸去甲肾上腺素注射液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4534977A (en)	1981-03-26	1985-08-13	American Cyanamid Company	Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4477452A (en)	1981-03-26	1984-10-16	American Cyanamid Company	Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4562073A (en)	1982-12-24	1985-12-31	Taiho Pharmaceutical Company Limited	Penicillin derivatives
US5763480A (en) *	1994-02-14	1998-06-09	The Jewish Hospital Of St. Louis	Inhibitors of cell-medicated disorders
US5580856A (en)	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) *	1996-08-21	2003-01-07	Micrologix Biotech Inc.	Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) *	1999-02-22	2001-03-27	Baxter International Inc.	Premixed formulation of piperacillin sodium and tazobactam sodium injection
EP1499341A4 (fr) *	2002-04-18	2010-10-27	Univ Iowa Res Found	Procede pour inhiber et traiter de films biologiques au moyen de chelateurs metalliques
ES2298672T3 (es)	2003-04-14	2008-05-16	Wyeth Holdings Corporation	Composiciones que contienen piperacilina y tazobactam utiles para inyeccion.
US6900184B2 (en)	2003-04-14	2005-05-31	Wyeth Holdings Corporation	Compositions containing pipercillin and tazobactam useful for injection
WO2004098643A1 (fr) *	2003-04-14	2004-11-18	Wyeth Holdings Corporation	Compositions d'injection contenant piperacilline et tazobactame

2004
- 2004-04-06 ES ES04076075T patent/ES2298672T3/es not_active Expired - Lifetime
- 2004-04-06 DE DE602004010862T patent/DE602004010862T2/de not_active Expired - Lifetime
- 2004-04-06 CN CN2004800159296A patent/CN1802179B/zh not_active Ceased
- 2004-04-06 EP EP04076075A patent/EP1468697B1/fr not_active Expired - Lifetime
- 2004-04-06 DK DK04076075T patent/DK1468697T3/da active
- 2004-04-06 PL PL04076075T patent/PL1468697T3/pl unknown
- 2004-04-06 AT AT04076075T patent/ATE381947T1/de active
- 2004-04-06 SI SI200430609T patent/SI1468697T1/sl unknown
- 2004-04-06 RU RU2005135135/15A patent/RU2322980C2/ru active
- 2004-04-06 PT PT04076075T patent/PT1468697E/pt unknown
- 2004-04-07 MX MXPA05010996A patent/MXPA05010996A/es active IP Right Grant
- 2004-04-07 US US10/553,139 patent/US7498312B2/en not_active Expired - Lifetime
- 2004-04-07 AU AU2004229407A patent/AU2004229407B2/en not_active Expired
- 2004-04-07 TW TW093109588A patent/TWI308069B/zh not_active IP Right Cessation
- 2004-04-07 GB GB0407853A patent/GB2400557B/en not_active Expired - Fee Related
- 2004-04-07 WO PCT/US2004/010698 patent/WO2004091666A1/fr not_active Ceased
- 2004-04-07 BR BRPI0409450A patent/BRPI0409450B8/pt not_active IP Right Cessation
- 2004-04-07 KR KR1020057019689A patent/KR100824554B1/ko not_active Expired - Lifetime
- 2004-04-07 NZ NZ543005A patent/NZ543005A/en not_active IP Right Cessation
- 2004-04-07 JP JP2006509780A patent/JP4644659B2/ja not_active Expired - Lifetime
- 2004-04-08 CA CA002464258A patent/CA2464258C/fr not_active Expired - Lifetime
- 2004-04-09 FR FR0403786A patent/FR2853547B1/fr not_active Expired - Fee Related
- 2004-04-09 MY MYPI20041292A patent/MY139099A/en unknown
- 2004-04-12 CL CL200400782A patent/CL2004000782A1/es unknown
- 2004-04-13 CH CH00641/04A patent/CH695185A9/fr not_active IP Right Cessation
- 2004-04-13 AR ARP040101237A patent/AR043863A1/es active IP Right Grant
- 2004-05-18 SA SA4250119A patent/SA04250119B1/ar unknown
2005
- 2005-10-07 CR CR8035A patent/CR8035A/es unknown
- 2005-10-10 IL IL171337A patent/IL171337A/en active IP Right Grant
- 2005-10-13 ZA ZA200508315A patent/ZA200508315B/en unknown
- 2005-10-14 EC EC2005006100A patent/ECSP056100A/es unknown
- 2005-10-18 NO NO20054789A patent/NO20054789L/no not_active Application Discontinuation
- 2005-11-09 CO CO05114116A patent/CO5700796A2/es not_active Application Discontinuation
2007
- 2007-11-16 RU RU2007142454/15A patent/RU2007142454A/ru not_active Application Discontinuation
2008
- 2008-03-04 CR CR9792A patent/CR9792A/es not_active Application Discontinuation
- 2008-03-06 CY CY20081100258T patent/CY1108064T1/el unknown
2009
- 2009-02-13 US US12/370,794 patent/US7915229B2/en not_active Expired - Lifetime
2011
- 2011-02-24 US US13/033,861 patent/US8133883B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2004229407A1 (en)	2004-10-28
NZ543005A (en)	2009-03-31
FR2853547B1 (fr)	2006-08-04
FR2853547A1 (fr)	2004-10-15
CA2464258C (fr)	2005-06-07
EP1468697B1 (fr)	2007-12-26
BRPI0409450A (pt)	2006-05-02
US20090176720A1 (en)	2009-07-09
AU2004229407B2 (en)	2010-04-22
SI1468697T1 (sl)	2008-04-30
BRPI0409450B1 (pt)	2016-07-12
ATE381947T1 (de)	2008-01-15
CN1802179A (zh)	2006-07-12
PT1468697E (pt)	2008-03-05
TW200503758A (en)	2005-02-01
GB2400557A (en)	2004-10-20
KR20060014375A (ko)	2006-02-15
JP2006523695A (ja)	2006-10-19
GB2400557B (en)	2005-06-15
MY139099A (en)	2009-08-28
CH695185A5 (fr)	2006-01-13
RU2322980C2 (ru)	2008-04-27
DE602004010862D1 (de)	2008-02-07
RU2005135135A (ru)	2006-06-10
NO20054789D0 (no)	2005-10-18
RU2007142454A (ru)	2009-05-27
CO5700796A2 (es)	2006-11-30
US8133883B2 (en)	2012-03-13
US20060234995A1 (en)	2006-10-19
JP4644659B2 (ja)	2011-03-02
PL1468697T3 (pl)	2008-05-30
ES2298672T3 (es)	2008-05-16
KR100824554B1 (ko)	2008-04-24
WO2004091666A1 (fr)	2004-10-28
IL171337A (en)	2011-03-31
ECSP056100A (es)	2006-03-01
DE602004010862T2 (de)	2009-01-02
SA04250119B1 (ar)	2008-03-30
WO2004091666A8 (fr)	2005-11-10
US20110166091A1 (en)	2011-07-07
CR9792A (es)	2008-09-23
EP1468697A1 (fr)	2004-10-20
US7498312B2 (en)	2009-03-03
CN1802179B (zh)	2011-09-14
TWI308069B (en)	2009-04-01
CA2464258A1 (fr)	2004-10-14
CY1108064T1 (el)	2014-02-12
DK1468697T3 (da)	2008-04-14
CR8035A (es)	2006-05-30
GB0407853D0 (en)	2004-05-12
CL2004000782A1 (es)	2005-03-04
ZA200508315B (en)	2008-04-30
BRPI0409450B8 (pt)	2021-05-25
US7915229B2 (en)	2011-03-29
CH695185A9 (fr)	2006-02-28
MXPA05010996A (es)	2005-12-12
HK1069775A1 (en)	2005-06-03
AR043863A1 (es)	2005-08-17

Publication	Publication Date	Title
NO20054789L (no)	2005-12-13	Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon
NZ600118A (en)	2014-08-29	Lipopeptide compositions and related methods
NZ602557A (en)	2014-09-26	Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TN2009000382A1 (en)	2010-12-31	Stable antibody formulations
MX2011013722A (es)	2012-05-08	Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
WO2004096133A3 (fr)	2005-12-22	Methode d'inhibition de l'activation cellulaire au moyen du facteur de croissance 1 analogue a l'insuline
AU3518300A (en)	2000-09-28	Highly soluble and stable mineral supplements
NZ756322A (en)	2021-12-24	Mechanism of urea/solid acid interaction under storage conditions and storage stable solid compositions comprising urea and acid
SG144075A1 (en)	2008-07-29	Protein stabilization formulations
CR20210224A (es)	2021-06-08	Compuestos de amoniácidos y métodos de uso
EP2260835A3 (fr)	2011-09-14	Composition destinée a inhiber le proteasome
TW200700092A (en)	2007-01-01	Tigecycline compositions and methods of preparation
WO2008128775A3 (fr)	2009-04-23	Composition pharmaceutique stabilisée contenant de la prégabaline
JO3406B1 (ar)	2019-10-20	عملية لتصنيع منتج صيدلاني يشتمل على حمض الستريك ،أكسيد ماغنسيوم، بيكربونات بوتاسيوم وبيكو كبريتات صوديوم، تركيبة صيدلانية تشتمل على حبيبات متحصل عليها بواسطة هذه العملية ومنتجات وسيطة منها
WO2008097842A3 (fr)	2008-12-18	Systèmes d'ingrédients comprenant du tréhalose, produits alimentaires comprenant du tréhalose, et procédés de fabrication de ceux-ci
EA202192646A1 (ru)	2021-12-09	Лиофилизированная композиция, содержащая соединение бензоазепина
WO2008100280A3 (fr)	2008-12-04	Compositions antimicrobiennes et procédés pour traiter des produits alimentaires emballés
WO2002004409A3 (fr)	2002-07-18	Agents neuroprotecteurs à base d'analogues de tétrahydrobenzothiazole
IL152406A0 (en)	2003-05-29	Anti-freeze proteins, their production and use
EP1682565A4 (fr)	2007-07-04	Oligomeres de nucleobases iap et complexes oligomeres, et leur utilisation
IL180384A0 (en)	2008-04-13	Ice-containing products
MX2008001560A (es)	2008-02-15	Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
WO2009080627A3 (fr)	2010-07-01	Kit comprenant un alginate et un agent complexant sous forme d'un sel soluble dans l'eau
AU2003224107A1 (en)	2003-11-11	Soluble composition containing sporopollenin and the use thereof
TW200505460A (en)	2005-02-16	Rosmarinic acid composition

Legal Events

Date	Code	Title	Description
2011-11-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application